Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up

This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy

Trial Details

NCT ID
NCT04290663
Phase
PHASE3
Sponsor
Centre Francois Baclesse
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • Systematic RAI-treatment
  • Decision of RAI-treatment guided by a post-operative assessment
Locations (sample)
  • Pointe à Pitre, Guadeloupe, France|44.07984,1.98937
  • Angers, France|47.47156,-0.55202
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017:
  • Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with \< 4 foci of vascular invasion) or Hürthle cell ca…
  • T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, wit…
  • T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →